Activin and Inhibin

GSK778 (iBET-BD1) is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC 50 s of 75 nM ( BRD2 BD1 ), 41 nM ( BRD3 BD1 ), 41 nM ( BRD4 BD1 ), and 143 nM ( BRDT BD1 ), respectively. GSK778 phenocopies the effects of pan- BET

GSK778 (iBET-BD1) is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC 50 s of 75 nM ( BRD2 BD1 ), 41 nM ( BRD3 BD1 ), 41 nM ( BRD4 BD1 ), and 143 nM ( BRDT BD1 ), respectively. GSK778 phenocopies the effects of pan- BET

GSK778 (iBET-BD1) is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC 50 s of 75 nM ( BRD2 BD1 ), 41 nM ( BRD3 BD1 ), 41 nM ( BRD4 BD1 ), and 143 nM ( BRDT BD1 ), respectively. GSK778 phenocopies the effects of pan- BET

GSK778 (iBET-BD1) is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC 50 s of 75 nM ( BRD2 BD1 ), 41 nM ( BRD3 BD1 ), 41 nM ( BRD4 BD1 ), and 143 nM ( BRDT BD1 ), respectively. GSK778 phenocopies the effects of pan- BET

GSK805 is an orally active and CNS penetrant RORγt inhibitor. GSK805 inhibits RORγ and Th17 cells differentiation with pIC 50 values of 8.4 and &gt:8.2. GSK805 inhibits the function of Th17 cells. GSK805 can be used for the research of immunityIn

GSK840 (GSK'840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC 50 of 0.9 nM, and inhibits kinase activity with an IC 50 of 0.3 nMIn VitroGSK840 (GSK'840) (0.01-3 μM: 24 hours) blocks

GSK840 (GSK'840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC 50 of 0.9 nM, and inhibits kinase activity with an IC 50 of 0.3 nMIn VitroGSK840 (GSK'840) (0.01-3 μM: 24 hours) blocks

GSK840 (GSK'840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC 50 of 0.9 nM, and inhibits kinase activity with an IC 50 of 0.3 nMIn VitroGSK840 (GSK'840) (0.01-3 μM: 24 hours) blocks

GSK840 (GSK'840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC 50 of 0.9 nM, and inhibits kinase activity with an IC 50 of 0.3 nMIn VitroGSK840 (GSK'840) (0.01-3 μM: 24 hours) blocks

GSK8573 is an inactive control compound for GSK2801 (acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains). GSK8573 has binding activity to BRD9 with a K d value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain

GSK8573 is an inactive control compound for GSK2801 (acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains). GSK8573 has binding activity to BRD9 with a K d value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain

GSK8573 is an inactive control compound for GSK2801 (acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains). GSK8573 has binding activity to BRD9 with a K d value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain